Pathfinder project: LeadtoTreat

LeadtoTreat seek to enable administration of poorly soluble lead compounds, synergistic pairs, in a rapidly tuneable nanoencapsulation platform, then use targeting moieties (e.g. nanobodies) to enhance particle efficacy.

N.A.

SINTEF is one the largest independent research institutes in northern Europe. We undertake research from fundamental to applied science across a wide range of fields within our 6 Institutes. As well as working directly for industry partners, we win the majority of our funding in open competition and participate in and co-ordinate large international project (e.g. Horizon Europe and m-Era Net).
The Department of Biotechnology and Nanomedicine offers a broad range services within biotechnology and medicine. This includes bioprospecting, bioprocess engineering, high throughput in-vitro screen (toxicity, activity etc), formulation (including nanoformulation), physiochemical characterisation and in-vivo studied. We have an extensive mass spectrometry instrument park. Antibiotic and anti-cancer activities are a particular focus.

SINTEF has access to novel patented lead candidates for MRSA treatment (e.g. MBL-AB01 Patent application ref NO20160680). We can offer an extensive range materials and methods for nanoformulation, characterisation and analysis. Notably we have high throughput robotic systems for toxicity and efficacy studies on a wide range of bacteria and cell lines, as well as support MS platforms. We can offer in-vivo toxicity and biodistribution studies.